Rhodiola rosea

Metadata

Approved Indications

Commission E (Germany)

• No original Commission E monograph (Rhodiola was not part of the German phytotherapy tradition during the Commission E period 1978-1994; primary traditional use was in Scandinavian, Russian, and Tibetan medicine)

ESCOP

• No ESCOP monograph identified for Rhodiola rosea. [NEEDS-RESEARCH for most recent ESCOP publications]

EMA/HMPC

• EU herbal monograph adopted (March 2012, Revision 1): EMA/HMPC/232091/2011
• Category: Traditional use registration
• Approved indication: “Traditional herbal medicinal product for the temporary relief of symptoms of stress, such as fatigue, exhaustion and mild anxiety”
• Herbal preparation covered: Dry extract of root and rhizome (DER 1.5-5:1), extraction solvent ethanol 60% (m/m)
• Age restriction: Adults only (18+)
• Duration: Short-term use recommended; consult a doctor if symptoms persist beyond 2 weeks

HMPC Assessment Basis

The HMPC conclusions are based on “traditional use” — meaning:

• Insufficient evidence from clinical trials alone to establish “well-established use”
• But effectiveness is plausible AND the product has been used safely for at least 30 years (including 15 years within the EU)
• The assessment acknowledged clinical trial evidence as supportive of plausibility
• Notable: Rhodiola is the main adaptogen approved by the HMPC/EMA for the indication “stress.” The HMPC Reflection Paper on the Adaptogenic Concept (2008) specifically discussed Rhodiola as a reference adaptogen.

Agreement/Disagreement

• Unique status: Rhodiola rosea is the ONLY adaptogen in this module with a formal EMA/HMPC monograph. This gives it a distinctive regulatory advantage over Eleuthero (which has a HMPC monograph but for asthenia rather than stress per se) and Astragalus (no EU recognition).
• Conservative classification: Despite multiple RCTs showing significant effects, the HMPC classified Rhodiola under “traditional use” rather than “well-established use,” reflecting cautious evidence assessment.

Conditions Treated

• Stress-related fatigue (HMPC-approved indication)
• Physical and mental exhaustion (HMPC-approved indication)
• Mild anxiety associated with stress (HMPC-approved indication)
• Cognitive performance under stress (fatigue, sleep deprivation)
• Mild to moderate depression (clinical trial evidence, not in HMPC indication)
• Exercise performance and recovery [UNCERTAIN — mixed evidence]
• Burnout syndrome [UNCERTAIN — limited formal evidence]

Mechanism of Action

Active Compounds

Species Authentication

The natural ratio of rosavins to salidroside in genuine R. rosea root is approximately 3:1. Standardized extracts aim to preserve this ratio (3% rosavins, 1% salidroside). Products not containing rosavins may be adulterated with other Rhodiola species (R. crenulata is a common adulterant that contains salidroside but not rosavins). [Source: Panossian & Wikman]

Adaptogenic Mechanisms

1. HPA axis modulation: Rhodiola regulates cortisol release under stress, preventing both excessive cortisol secretion (during acute stress) and cortisol depletion (during chronic stress). Normalizes the stress response rather than simply suppressing it. [Source: PMC9228580]

2. Monoamine neurotransmitter effects: At low doses, R. rosea stimulates norepinephrine, dopamine, and serotonin activity in the CNS. Increases permeability of the blood-brain barrier to precursors of dopamine and serotonin, improving cerebral neurotransmitter availability. [Source: Drugs.com monograph]

3. Molecular chaperones (Heat Shock Proteins): Rhodiola upregulates HSP70 and Hsp72 expression, protecting cells from stress-induced damage. This is a key molecular mechanism of the adaptogenic effect. [Source: Panossian et al.]

4. Neuroprotective effects: Salidroside protects neurons from oxidative stress-induced apoptosis. Demonstrated in models of neurodegeneration and ischemia. Non-genotoxic at clinical doses. [Source: PMC5973445]

5. Nitric oxide modulation: Effects on NO production may contribute to cardiovascular and cognitive benefits

6. AMPK activation: Salidroside activates AMP-activated protein kinase, linking to metabolic and anti-fatigue effects

Dose-Response Relationship (Inverted U-Curve)

Rhodiola exhibits a characteristic inverted U-shaped dose-response curve: low-to-moderate doses are stimulating and performance-enhancing, while very high doses may be sedating or show reduced efficacy. This is consistent with adaptogenic pharmacology and has implications for clinical dosing. Doses above 680 mg/day may be less effective than moderate doses. [Source: Examine.com, Integrative Therapeutics]

Clinical Evidence Summary

Key RCTs

Depression Trial Details (Darbinyan 2007)

• Population: Patients with ICD-10 mild to moderate depression (HAMD scores 21-31)
• Three groups: SHR-5 340 mg/day (n=31), SHR-5 680 mg/day (n=29), placebo (n=29)
• Both active groups showed significant improvement in overall HAMD scores vs. placebo
• Insomnia and emotional instability improved most
• Self-esteem did not significantly improve
• No serious adverse events
• [Source: Pubmed 17990195]

Evidence Quality Assessment

• Most trials are small (n=56-161)
• Consistent positive results across different populations (physicians, students, patients with fatigue, patients with depression)
• SHR-5 extract is used across most pivotal studies, providing product consistency
• Many key studies come from Scandinavian and Armenian research groups; independent replication is moderate
• No Cochrane systematic review exists for Rhodiola

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• No absolute contraindications identified in the HMPC monograph
• Bipolar disorder: Theoretical risk of triggering mania (as with all substances affecting monoamines) [UNCERTAIN]
• Severe anxiety disorders: Stimulating properties at higher doses could theoretically worsen anxiety
• Children and adolescents: HMPC restricts to adults 18+ due to insufficient pediatric data

Drug Interactions

• CYP3A4 inhibition: Potent in vitro inhibition. Clinical significance unclear but warrants caution with CYP3A4 substrates (statins, calcium channel blockers, some immunosuppressants, benzodiazepines, many others)
• CYP2C9 inhibition: 21% decrease in CYP2C9 activity at 580 mg/day for 14 days. Affects warfarin, phenytoin, NSAIDs, sulfonylureas. [Source: Drugs.com]
• P-glycoprotein inhibition: Potent in vitro. May increase bioavailability of P-gp substrates.
• Antidepressants: Combination with prescription SSRIs, SNRIs, or MAOIs may cause excessive serotonergic/noradrenergic stimulation; tachycardia reported. [Source: WebMD]
• Blood sugar-lowering drugs: Additive hypoglycemia possible
• Surgery: Recommend discontinuation 2 weeks before surgery due to CYP2C9 effects and potential interactions with anesthetics [Source: Drugs.com]
• Overall: Drug interaction risk is MODERATE — higher than most herbs in this module due to CYP enzyme inhibition

Side Effects

• Very well tolerated at clinical doses
• Mild: Dizziness, dry mouth, jitteriness (usually at initiation or higher doses)
• Insomnia (if taken late in the day — stimulating effect)
• Excessive salivation (rare)
• LD50: 28.6 mL/kg intraperitoneally in mice (equivalent to ~235 g for a 70 kg human), providing a massive safety margin vs. clinical doses of 200-600 mg/day

Pregnancy/Lactation

• Pregnancy: Insufficient data. Not recommended. HMPC monograph does not include pregnancy in approved populations.
• Lactation: Insufficient data. Not recommended.

Clinical Dosage

SHR-5 Standardized Extract

• Anti-fatigue/adaptogenic (daily preventive): 100-200 mg/day
• Acute anti-fatigue (stress periods): 288-680 mg/day
• Depression: 340-680 mg/day (per Darbinyan 2007)
• Maximum recommended: 680 mg/day (higher doses may have reduced efficacy — inverted U-curve)
• Timing: Morning or early afternoon (avoid evening dosing due to stimulating effects)
• Duration: Short-term courses (2-6 weeks recommended by HMPC; longer use possible but should be supervised)

Standardization Requirements

• Rosavins: Minimum 3% (specific to R. rosea; marker for authenticity)
• Salidroside: Minimum 0.8-1%
• Products standardized only to salidroside (without rosavins) may contain adulterant species

Key Commercial Products

• SHR-5 (Swedish Herbal Institute): The original clinically studied extract; basis for most clinical trials. Available as Rosavin, WS 1375, and various licensed products.
• Vitano (Dr. Willmar Schwabe): European THR product containing WS 1375 extract (200 mg per tablet). Available in Germany and UK under traditional use registration.
• Rhodiola Rosea EP (various): European Pharmacopoeia-quality raw material
• Arctic Root (Swedish Herbal Institute): Consumer brand for SHR-5
• Rhodax (various): Clinical-grade Rhodiola in Scandinavian markets

Sources

• EMA/HMPC: European Union herbal monograph on Rhodiola rosea L., rhizoma et radix (EMA/HMPC/232091/2011, Revision 1, adopted March 2012)
• EMA/HMPC: Assessment report on Rhodiola rosea L., rhizoma et radix (Revision 1)
• Darbinyan V et al. “Rhodiola rosea in stress induced fatigue.” Phytomedicine. 2000;7(5):365-371.
• Darbinyan V et al. “Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.” Nord J Psychiatry. 2007;61(5):343-348. (Pubmed 17990195)
• Shevtsov VA et al. “A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work.” Phytomedicine. 2003;10(2-3):95-105. (Pubmed 12725561)
• Olsson EM et al. “A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of Rhodiola rosea in the treatment of subjects with stress-related fatigue.” Planta Med. 2009;75(2):105-112. (Pubmed 19016404)
• Panossian A et al. “The Effectiveness of Rhodiola rosea L. Preparations in Alleviating Various Aspects of Life-Stress Symptoms.” Molecules. 2022;27(12):3902. (PMC9228580)
• HMPC Reflection Paper on the Adaptogenic Concept (EMEA/HMPC/598082/2007)
• Panossian A, Wikman G. “Stress management and the role of Rhodiola rosea.” Int J Psychiatry Clin Pract. 2018;22(4):242-252.
• Health Canada: Natural Health Products Monograph — Rhodiola rosea (2019)

Connections

• Eleuthero: Fellow adaptogen; both have HMPC recognition; Eleuthero for “asthenia” vs. Rhodiola for “stress”
• Astragalus: Both classified as adaptogens; Astragalus lacks EU recognition entirely
• Andrographis: Component of Kan Jang (with Eleuthero, not Rhodiola) but similar research lineage (Panossian group)